IAVI

Media & Resources

Filter by

  • Type

  • Health area

  • Location

  • Topic

  • Year

  • Journal

  • Publication

  • Fact sheet & publication type

  • Clear all

Features

IAVI salutes commitments to TB vaccine R&D

June 29, 2023

Wellcome and Gates Foundation announce plans to fund a Phase III clinical trial of the tuberculosis vaccine candidate M72 in adults.

Read more

Press Releases

IAVI starts first-in-human Phase 1 clinical trial of single-dose Sudan virus vaccine candidate

June 27, 2023

NEW YORK – JUNE 27, 2023 – IAVI announced today that the first participants have been vaccinated with a Sudan virus (SUDV) vaccine candidate in a first-in-human Phase 1 clinical trial in the U.S. The IAVI-sponsored trial is funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness…

Read more

IAVI Report

Powering up African-based data centers

June 22, 2023

COVID-19 illustrated once again the importance of localized epidemiological data, monitoring, and analysis.

Read more

Features

Three new articles highlight the health economics of HIV prevention technologies

June 8, 2023

This series of articles in PharmacoEconomics are designed to map evidence gaps and identify health economic research priorities for the HIV prevention field.

Read more

Features

Meet The Scientist podcast: An interview with Gabriela Gomez, senior director of global access at IAVI

June 6, 2023

The first episode of Meet The Scientist, IAVI’s new podcast series, will explore the importance of economic modeling for TB vaccine R&D.

Read more

Scientific Publications

Geographic mobility and treatment outcomes among people in care for tuberculosis in the Lake Victoria region of East Africa: A multi-site prospective cohort study

Read more

Podcasts

Meet The Scientist Episode 1: Gabriela Gomez

June 1, 2023

In Amsterdam, we sat down with Gabriela Gomez, senior director of global access at IAVI, to discuss her work using modeling to understand the potential impact of a new tuberculosis (TB) vaccine. As the COVID-19 pandemic has waned, TB once again has become the leading infectious cause of death in much of the world. In 2021, an estimated 1.6 million people died as a result of TB disease, making a new TB vaccine all the more vital. Gabriela Gomez also uses modeling to better understand how a new TB vaccine can be developed and distributed in an equitable and accessible way.This podcast will explore the importance of epidemiology—a branch of medical science that investigates all the factors that determine the presence or absence of diseases—in TB vaccine R&D and global health access in general. Listen to the first episode of our new series Meet The Scientist to learn more about how IAVI is using epidemiology to develop affordable, globally accessible vaccines and antibodies.

Read more

In The News

Six HIV vaccines in research and development in the US, Rwanda, South Africa and Kenya

Daily Maverick

May 30, 2023

Read more